MX2015011671A - Co-administracion de esteroides y acido zoledronico para prevenir y tratar la osteoartritis. - Google Patents
Co-administracion de esteroides y acido zoledronico para prevenir y tratar la osteoartritis.Info
- Publication number
- MX2015011671A MX2015011671A MX2015011671A MX2015011671A MX2015011671A MX 2015011671 A MX2015011671 A MX 2015011671A MX 2015011671 A MX2015011671 A MX 2015011671A MX 2015011671 A MX2015011671 A MX 2015011671A MX 2015011671 A MX2015011671 A MX 2015011671A
- Authority
- MX
- Mexico
- Prior art keywords
- zoledronic acid
- administration
- steroids
- osteoarthritis
- prevent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se revela una terapia de combinación para tratar la osteoartritis. La terapia de combinación incluye la co- administración de un esteroide y Ácido Zoledrónico. La coadministración de un esteroide reduce la producción de citocinas y, en consecuencia, reduce los efectos proinflamatorios del Ácido Zoledrónico. La co-administración del Ácido Zoledrónico con esteroides trata la osteoartritis y contribuye a prevenir el inicio de la osteoartritis en pacientes en riesgo de desarrollar osteoartritis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/791,685 US9012432B2 (en) | 2013-03-08 | 2013-03-08 | Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis |
| PCT/US2014/022169 WO2014138712A1 (en) | 2013-03-08 | 2014-03-07 | Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015011671A true MX2015011671A (es) | 2016-05-12 |
Family
ID=51488530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015011671A MX2015011671A (es) | 2013-03-08 | 2014-03-07 | Co-administracion de esteroides y acido zoledronico para prevenir y tratar la osteoartritis. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9012432B2 (es) |
| EP (1) | EP2964209B1 (es) |
| JP (2) | JP6839491B2 (es) |
| KR (1) | KR102253394B1 (es) |
| CN (1) | CN105324113B (es) |
| AU (1) | AU2014225373B2 (es) |
| BR (1) | BR112015021503B1 (es) |
| CA (1) | CA2941346C (es) |
| EA (1) | EA032067B1 (es) |
| ES (1) | ES2904365T3 (es) |
| MX (1) | MX2015011671A (es) |
| WO (1) | WO2014138712A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10913772B2 (en) | 2016-03-09 | 2021-02-09 | Kine Sciences Co., Ltd. | Peptide for preventing or treating inflammatory diseases and use thereof |
| US10913771B2 (en) | 2016-03-09 | 2021-02-09 | Kine Sciences Co., Ltd. | Peptide for preventing or treating inflammatory diseases and use thereof |
| WO2017155234A1 (ko) | 2016-03-09 | 2017-09-14 | 주식회사 바이오펩 | 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도 |
| EP3428178A4 (en) | 2016-03-09 | 2019-09-04 | Bio Pep Co., Ltd. | PEPTIDE FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES AND USE THEREOF |
| KR101897122B1 (ko) | 2016-03-09 | 2018-09-10 | 주식회사 바이오펩 | 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도 |
| JP7127616B2 (ja) | 2019-06-04 | 2022-08-30 | 横河電機株式会社 | 情報処理装置、アラーム管理システム、及びアラーム管理方法 |
| WO2021163432A1 (en) * | 2020-02-12 | 2021-08-19 | Levolta Pharmaceuticals, Inc. | Co-administration of prednisolone/methyl prednisolone and zoledronic acid to treat and prevent osteoarthritis |
| CN114028571B (zh) * | 2021-11-18 | 2023-04-28 | 中国医学科学院基础医学研究所 | 含氮双膦酸盐联合糖皮质激素在预防或治疗病毒性肺炎中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2038692T4 (es) | 1986-11-21 | 2012-02-10 | Novartis Ag | Procedimiento para la obtencion de acidos alcanodifosfonicos substituidos. |
| GB0029111D0 (en) * | 2000-11-29 | 2001-01-10 | Novartis Ag | Organic compounds |
| MXPA03011330A (es) * | 2001-06-08 | 2004-12-06 | Johnson & Johnson | Tratamiento del dolor mediante el direccionamiento de canales que se abren por un nucleotido ciclico, activados mediante hiperpolarizacion. |
| US20030195171A1 (en) * | 2002-04-05 | 2003-10-16 | Daifotis Anastasia G. | Method for inhibiting bone resorption with an alendronate and vitamin D formulation |
| WO2005123193A2 (en) * | 2004-06-17 | 2005-12-29 | Osteologix A/S | Treatments comprising strontium for rheumatic and arthritic diseases and pain |
| KR20060058134A (ko) * | 2003-09-19 | 2006-05-29 | 화이자 프로덕츠 인코포레이티드 | 2-알킬리덴-19-노르-비타민 디 유도체 및비스포스포네이트의 조합을 포함하는 약학 조성물 및 방법 |
| JP5240925B2 (ja) * | 2005-05-25 | 2013-07-17 | カロシン ファーマ， インコーポレイテッド | 変形性関節症を処置するための方法および組成物 |
| US20070048372A1 (en) * | 2005-08-18 | 2007-03-01 | Srz Properties, Inc. | Method for treating non-inflammatory osteoarthritic pain |
| PT2049123E (pt) * | 2006-08-03 | 2013-03-06 | Horizon Pharma Ag | Tratamento de doença reumatóide com glucocorticóide de libertação retardada |
| WO2010071866A2 (en) * | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Combination therapy for arthritis with tranilast |
| MX2011011698A (es) * | 2009-05-04 | 2012-02-29 | Zars Pharma Inc | Metodo para tratar dolores asociados con neuroma, entrapamiento nervioso y otras condiciones. |
| US8946199B2 (en) | 2010-04-26 | 2015-02-03 | Ketan Desai | Co-administration of steroids and Zoledronic acid to prevent and treat side effects from Zoledronic acid infusion |
-
2013
- 2013-03-08 US US13/791,685 patent/US9012432B2/en active Active - Reinstated
-
2014
- 2014-03-07 CN CN201480026349.0A patent/CN105324113B/zh active Active
- 2014-03-07 MX MX2015011671A patent/MX2015011671A/es active IP Right Grant
- 2014-03-07 BR BR112015021503-3A patent/BR112015021503B1/pt active IP Right Grant
- 2014-03-07 CA CA2941346A patent/CA2941346C/en active Active
- 2014-03-07 KR KR1020157027348A patent/KR102253394B1/ko active IP Right Grant
- 2014-03-07 AU AU2014225373A patent/AU2014225373B2/en active Active
- 2014-03-07 EA EA201591638A patent/EA032067B1/ru not_active IP Right Cessation
- 2014-03-07 WO PCT/US2014/022169 patent/WO2014138712A1/en active Application Filing
- 2014-03-07 EP EP14761174.3A patent/EP2964209B1/en active Active
- 2014-03-07 JP JP2015561747A patent/JP6839491B2/ja active Active
- 2014-03-07 ES ES14761174T patent/ES2904365T3/es active Active
-
2019
- 2019-04-03 JP JP2019071500A patent/JP2019104762A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015021503A2 (pt) | 2018-05-15 |
| KR102253394B1 (ko) | 2021-05-20 |
| CN105324113A (zh) | 2016-02-10 |
| AU2014225373A1 (en) | 2015-10-22 |
| JP2016510765A (ja) | 2016-04-11 |
| JP2019104762A (ja) | 2019-06-27 |
| BR112015021503B1 (pt) | 2022-09-06 |
| CN105324113B (zh) | 2018-07-03 |
| AU2014225373B2 (en) | 2018-07-05 |
| CA2941346A1 (en) | 2014-09-12 |
| EP2964209B1 (en) | 2021-10-27 |
| ES2904365T3 (es) | 2022-04-04 |
| EP2964209A4 (en) | 2016-08-03 |
| CA2941346C (en) | 2020-03-10 |
| EA032067B1 (ru) | 2019-04-30 |
| JP6839491B2 (ja) | 2021-03-17 |
| US20140256681A1 (en) | 2014-09-11 |
| KR20150125001A (ko) | 2015-11-06 |
| EP2964209A1 (en) | 2016-01-13 |
| EA201591638A1 (ru) | 2016-02-29 |
| WO2014138712A1 (en) | 2014-09-12 |
| US9012432B2 (en) | 2015-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015011671A (es) | Co-administracion de esteroides y acido zoledronico para prevenir y tratar la osteoartritis. | |
| MX2021004821A (es) | Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. | |
| MX2016005532A (es) | Metodos para usar oxido nitrico en un estado de plasma para tratar condiciones medicas y enfermedades. | |
| PH12014502048B1 (en) | Treatment of cancer with tor kinase inhibitors | |
| WO2014197632A3 (en) | Methods, systems and devices for reducing the luminal surface area of the gastrointestinal tract | |
| PH12014502046A1 (en) | Treatment of cancer with tor kinase inhibitors | |
| BR112017018964A2 (pt) | uso de plinabulin e métodos para tratar tumor cerebral | |
| MX368286B (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer. | |
| IN2015DN00450A (es) | ||
| MX2015014599A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer. | |
| EP3071280A4 (en) | TREATMENT CATHETER COMPRISING THE ADMINISTRATION OF THERAPEUTIC ENERGY | |
| SA515370011B1 (ar) | طرق لعلاج سرطان باستخدام علاج توليفي من مركب داي هيدرو بيرازينو-بيرازين | |
| MX2020001727A (es) | Terapia de combinacion. | |
| MX2019013862A (es) | Terapia de combinacion. | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| MX2017011237A (es) | Alteracion del metabolismo de esteroides para el tratamiento de enfermedades dependientes de esteroides. | |
| MX2021014120A (es) | Tratamiento de los sintomas asociados a terapia privacion de androgenos. | |
| MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
| MX2017013668A (es) | Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer. | |
| RU2014150855A (ru) | Способ лечения сексуальной дисфункции у пациентов с хроническим простатитом | |
| UA84693U (ru) | Способ лечения больных неалкогольным стеатогепатитом в сочетании с хроническим бронхитом на фоне ожирения | |
| UA75277U (ru) | Способ лечения дистрофических заболеваний сетчатки и хориоидеи | |
| UA88769U (uk) | Спосіб профілактики та лікування доброякісних дисплазій молочних залоз у жінок з ранніми втратами вагітності | |
| UA86338U (ru) | Способ лечения беременных с гестационным диабетом | |
| UA93178U (uk) | Спосіб лікування хронічного тонзиліту у дітей |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |